Alvotech announces positive top-line results from a pharmacokinetic study for avt05, a proposed biosimilar for simponi® and simponi aria®

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for avt05, a biosimilar candidate to simponi® and simponi aria® (golimumab). the study, which assessed the pharmacokinetics, safety, and tolerability of avt05 compared to simponi in healthy adult subjects, met its primary endpoints.
ALVO Ratings Summary
ALVO Quant Ranking